AzurRx BioPharma is based in Brooklyn and specializes in developing non-systemic biologics for patients with gastrointestinal disorders. The company has 12 full-time employees and a product pipeline that includes two therapeutic proteins: MS1819 and AZX1101. MS1819 is designed to treat exocrine pancreatic insufficiency, while AZX1101 aims to prevent hospital-acquired infections and antibiotic-associated diarrhea.